Glembatumumab vedotin  (Synonyms: CDX-011; CR011-vcMMAE)

Glembatumumab vedotin (CDX-011) is an ADC (antibody-drug conjugates (ADCs)) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects^[1].

Glembatumumab vedotin binds to GPNMB on tumors, the complex is internalized and MMAE is released via proteolytic cleavage of the vc linker in a lysosomal compartment. Tumor cell death occurs as a result of microtubule inhibition by MMAE with resultant cell cycle arrest^[1].
Glembatumumab vedotin (1-125 μg/mL; 96 hours) demonstrates osteosarcoma cytotoxic activity^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Glembatumumab vedotin (CR011-vcMMAE; 1.25-80 mg/kg; i.v.; every 4 days; for 16 days) shows short-term anti-tumor effects (inhibition of tumor growth) and long-term effects (complete regression) in human SK-MEL-2 and SK-MEL-5 melanoma xenografts^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1182215-65-1

Liquid

Colorless to light yellow

[Glembatumumab vedotin]

Shipping with dry ice.

-80°C, protect from light

• [1]. Christopher H Keir, et al. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin Biol Ther. 2012 Feb;12(2):259-63.  [Content Brief]

  [2]. Vincent A Pollack, et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol. 2007 Aug;60(3):423-35.  [Content Brief]

  [3]. Michael Roth, et al. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatr Blood Cancer. 2016 Jan;63(1):32-8.  [Content Brief]